biostudies-literatureFiles DCNHLBI NIH HHS100168https://www.ebi.ac.uk/biostudies/studies/S-EPMC12823136biostudies-literatureUnknown3(3)<h4>Background</h4>A phase 2 trial of high-dose IV ascorbate suggested reduced mortality in patients with ARDS, although trials in sepsis have failed to show clinical benefit.<h4>Research question</h4>Does IV high-dose ascorbate improve outcomes in patients with sepsis at risk of or with ARDS?<h4>Study design and methods</h4>In this phase 2b multicenter randomized placebo-controlled trial, patients with known or suspected infection and either shock or acute hypoxemic respiratory failure were randomized to ascorbate (50 mg/kg IV every 6 hours for 5 days) or a matching placebo. The primary outcome was days alive and free of respiratory, renal, and circulatory organ support to day 28. Secondary outcomes included clinical and biological end points.<h4>Results</h4>After enrolling 79 participantCHEST critical careAscorbate for Organ Dysfunction in Critically Ill Patients With Sepsis: The Phase 2b ASTER Trial.PMC12823136U01 HL122998U01 HL122989U01 HL123008U01 HL123009U01 HL123018U01 HL123004U01 HL123027U01 HL123022U01 HL123033U01 HL123023U01 HL123020U01 HL123031U01 HL123010Hendey GWGinde AChang SYAggarwal NRGibbs KWTidswell MAMoskowitz AGoodwin ARobinson BRHFowler AABrown SMMiller CSelf WHWare LBBrower RGKhan AYealy DMHibbert KLiu KDRiker RThompson BTMatthay MAHough CLHuang WFields SHarris ESFiles DCDuggal ALai PDouglas ISHite RDFoulkes ASfalseAscorbate for Organ Dysfunction in Critically Ill Patients With Sepsis: The Phase 2b ASTER Trial.<h4>Background</h4>A phase 2 trial of high-dose IV ascorbate suggested reduced mortality in patients with ARDS, although trials in sepsis have failed to show clinical benefit.<h4>Research question</h4>Does IV high-dose ascorbate improve outcomes in patients with sepsis at risk of or with ARDS?<h4>Study design and methods</h4>In this phase 2b multicenter randomized placebo-controlled trial, patients with known or suspected infection and either shock or acute hypoxemic respiratory failure were randomized to ascorbate (50 mg/kg IV every 6 hours for 5 days) or a matching placebo. The primary outcome was days alive and free of respiratory, renal, and circulatory organ support to day 28. Secondary outcomes included clinical and biological end points.<h4>Results</h4>After enrolling 79 participant2025-01-01T00:00:00Z2025 Sep2026-06-06T22:05:10.222Z2026-06-05T03:12:20.124ZS-EPMC128231364157411710.1016/j.chstcc.2025.100168